Drug intelligence / Profile preview

IN-114199

Development stage: Phase 1
Lead developer: HK inno.N Corporation
Modality: Small Molecules
Administration: Oral

Overview

IN-114199 is an investigational small molecule drug developed by HK inno.N (formerly CJ Healthcare) as an ileal bile acid transporter (IBAT) inhibitor for the treatment of constipation. IBAT inhibitors work by blocking the reabsorption of bile acids in the ileum, which increases colonic secretion and motility, thereby alleviating constipation. The drug is currently being evaluated in early-phase clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adults[1][2][4].

Targets

SLC10A2 (Solute carrier family 10 member 2)

Beyond the preview

Go deeper on IN-114199.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IN-114199.